Dactolisib is a dual ATP competitive PI3K and mTOR inhibitor, which has been proven to have certain effects on tumors (59, 60), inflammatory diseases (61), polycystic kidney disease (62), and Alzheimer’s disease (63). This evidence concerns the gene MTOR and Alzheimer disease.